P-0002 Expression of HO-1 and its Correlation with Cliniclopathological Features in Esophageal Squamous Cell Carcinoma

Abstract

ABSTRACT Introduction Although esophageal adenocarcinoma is the most rapidly increasing cancer in Western countries, esophageal squamous cell carcinoma (ESCC) is still the dominant in East Asia, and one-half of all ESCC cases in the world occur in China. HO-1(Heme oxygenase-1), the initial and rate-limiting enzyme in heme catabolism, is a key protein that plays an important role in the cellular adaptation to stress inflicted by pathological events. Overexpression of HO-1 is very common events in many tumors, such as lymphosarcoma, hepatoma, prostate and pancreatic cancers. Recently, it has been implicated in tumor cell invasion, apoptosis, proliferation, metastasis and resistance to therapies. However, little is known about its expression in esophageal squamous cell carcinoma (ESCC) tissues and its relationship to various clinicopathological parameters. In this study, we aimed to investigate the expression of HO-1 and its correlation with clinicopathological features in ESCC. Methods The expression of HO-1 in 45 cases of EC tissues, 40 cases of adjacent tissues, 31 positive Lymph node tissues and 35 negative Lymph node tissues was assessed by SP immunohistochemical method. Results The main location of HO-1 was nuclear, and the highly positive rates of HO-1 in the cancer tissues was 71.11%(32/45), while that in the adjacent tissues group was 11.11%(5/45), and showed 78.12% (25/31) and 22.86%(8/35) in the positive Lymph node tissues and negative Lymph node tissues respectively, there is a significant difference between the two groups (P 0.05). Conclusion HO-1 may be a potential biomarker for initiation, progression, and differentiation of human ESCC. Our results show that HO-1 has high expression in ESCC tissues and positive Lymph node tissues, and the positive rate was closely correlated with the lymph node metastasis and degree of tumor differentiation, The HO-1 may play an important role in ESCC oncogenesis and drug resistence.